<- Home <- Arhive <- Vol. 8, Issue 2, May 2012



GINECOeu8(2)66-68(2012)
© gineco.eu


Endometriosismedroxiprogesterone versus triptorelinum

C. Cristescu, A. Veliscu, B. Marinescu, C. Damian


Abstract: To assess which is better for the treatment of endometriosis diagnosed laparoscopically: medroxiprogesteron or triptorelinum? The present study is a comparative study between two types of pharmacological treatment of endometriosis diagnosed laparoscopically, which could not be fully resolved surgically. Distribution is the following: in first group of patients receiving medroxiprogesterone depot 150 mg/intramuscular once a month, in the second group receiving Triptorelinum 3.75 mg/intramuscular every 4 weeks. After 6 months of drug treatment, patients in the two groups are subjected to second-look laparoscopic surgery to be able to compare the effectiveness of two types of medication. The study is still in progress because we are still enrolling patients. Until now we have completed the evaluation of 13 women (five received medroxiprogesteron and eight received triptorelinum). At the second look laparoscopy we found that 7 out of 8 patients from the triptorelinum group had a degree of endometriosis recurrence and three out of the five patients who tolerated medroxiprogesteron had no endometriosis recurrence. In these particular cases we were able to observe that for our patients medroxiprogesteron is more poorly tolerated than triptorelinum but with better results regarding endometriosis recurrence and symptomatology.
Keywords: endometriosis, medroxiprogesteron, triptorelinum

Full Text in PDF
© 2008-2024 gineco.eu. All rights reserved
created by if else factory